BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 15, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2024

View Archived Issues
Cell research illustration

ISSCR 2024: iPS cell line panels can be isogenic and diverse

The big advantage of cell culture to model diseases is its throughput. “You can play the disease over and over again in the dish,” Clive Svendsen told the audience at the International Society of Stem Cell Research (ISSCR) Annual Meeting held in Hamburg last week. That high throughput, however, is not particularly useful if the cell lines themselves do not accurately model the disease. Cancer cell lines are used in many cell culture experiments far beyond cancer for their ability to grow. But they are “highly abnormal,” Bill Skarnes told the audience at an innovation showcase, as well as quite unstable. “I don’t think the [HEK-293] cell line is the same in your lab as it is in the lab next door,” Skarnes said. Read More

TRPC5 loss causes obesity and anxiety-like disorders in rats

The hypothalamus controls several neural circuits that have to do with instinctive behaviors such as food seeking, socialization and offspring maternal care, among others. There is limited knowledge regarding the mechanisms by which internal and external sensory cues are integrated to coordinate innate behavior. Read More
respiratory-red-lungs

Addex reports findings with GABA-B PAM in guinea pig model of chronic cough

Addex Therapeutics Ltd. has released promising results from its novel γ-aminobutyric acid subtype B receptor (GABA-B) positive allosteric modulator (PAM) chronic cough program. In models of chronic cough in guinea pigs, the candidate GABA-B PAM significantly and dose-dependently reduced citric acid-induced cough frequency and increased cough latency. Read More
Silhouette of child and brain

Reactivation of UBE3A gene to treat Angelman syndrome

Epigenetic desilence of the paternal allele of the gene that causes Angelman syndrome (AS) could be used to treat this disease for which there are currently no approved therapies. Read More

FZ-AD005 overcomes shortcomings of other DLL3-targeted ADC for small-cell lung cancer

Delta-like protein 3 (DLL3) is a transmembrane protein overexpressed in the majority of neuroendocrine carcinomas of the lung such as small-cell lung cancer (SCLC). The first DLL3-targeted antibody-drug conjugate (ADC), rovalpituzumab tesirine (Rova-T), led to serious adverse events in clinical testing and its development was discontinued. Read More
women-gyno-uterus-ovary

TINAGL1 expression in follicular fluid as a biomarker of diminished ovarian reserve

A team at Massachusetts General Hospital conducted research to evaluate the expression levels of the extracellular matrix protein tubulointerstitial nephritis antigen-like 1 (TINAGL1) in the human ovary. Read More

‘We're always on the lookout for what's next’

From no hope to viable treatments, BioWorld  is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld  team is ‘always on the lookout for what's next.’ Read More

Immuneage Bio launches with focus on rejuvenating the immune system by targeting HSCs

Immuneage Bio has announced its launch, with $2 million in funding and a focus on rejuvenating the immune system by targeting hematopoietic stem cells (HSCs) residing in the bone marrow. Read More
Eya and DNA illustration

Rznomics gains Australian clearance to advance RZ-004 into clinic for retinitis pigmentosa

Rznomics Inc. has received clinical trial notification (CTN) from Australia’s Therapeutic Goods Administration (TGA) for the initiation of a phase I/IIa trial evaluating RZ-004, a gene therapeutic candidate for autosomal dominant retinitis pigmentosa with rhodopsin mutation. Read More

Cytokinetics patents new Nampt activators

Cytokinetics Inc. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) activators reported to be useful for the treatment of cancer, neurodegeneration, mitochondrial and metabolic diseases, cardiovascular, muscle, renal and inflammatory disorders, among others. Read More

Hua Medicine divulges new KHK inhibitors

Hua Medicine (Shanghai) Co. Ltd. has synthesized ketohexokinase (KHK) inhibitors reported to be useful for the treatment of gout, stroke, coronary artery disease, irritable bowel syndrome, diabetes, cataracts, fibrosis and obesity. Read More
Illustration of interaction between PD-1 and PD-L1 blocked by therapeutic antibodies

Combining PD-L1 blockade with pharmacological HPK1 inhibition overcomes tumors with low antigenicity

An article by Daiichi Sankyo Co. Ltd. scientists reports data from a study designed to assess the potential of combining pharmacological inhibition of hematopoietic progenitor kinase 1 (HPK1) with programmed cell death 1 ligand 1 (PD-L1) blockade as a novel strategy to enhance antitumor immunity against tumors with low antigenicity. Read More

University of Florida describes new σ receptor ligands

University of Florida has identified σ receptor ligands reported to be useful for the treatment of cancer, depression, neurodegeneration, stroke, pain, multiple sclerosis, schizophrenia and anxiety. Read More

New IRE1 inhibitors disclosed in Shanghai Yi Zhong Xing Biotechnology patent

Shanghai Yi Zhong Xing Biotechnology Co. Ltd. has divulged serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) inhibitors reported to be useful for the treatment of cancer. Read More
Photomicrograph of hepatocellular carcinoma

Chinese researchers verify GCN5L1 involvement in HCC sensitivity to sorafenib

Resistance to sorafenib treatment is becoming more common in hepatocellular carcinoma (HCC). Iron is a crucial metal in the mitochondria and is used for synthesis of cofactors that are essential for the correct functioning and cell proliferation. Read More

Korea Institute of Science and Technology discovers new diosgenin derivatives

Korea Institute of Science and Technology has described diosgenin derivatives reported to be useful for the treatment of depression, multiple sclerosis, ischemic stroke, schizophrenia, amyotrophic lateral sclerosis, neuroblastoma, Alzheimer’s disease and post-traumatic stress disorders. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 12, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • CT scan of brain showing subdural hematoma

    FDA greenlights Medtronic Onyx subdural hematoma treatment

    BioWorld MedTech
    Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing